BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06 2022 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
that the compensation committee of BioCryst’s board of directors
granted 17 newly-hired employees stock options to purchase an
aggregate of 161,500 shares, and restricted stock units (RSUs)
covering an aggregate of 64,250 shares, of BioCryst common stock.
The options and RSUs were granted as of August 31, 2022 as
inducements material to each employee entering into employment with
BioCryst. The options and RSUs were granted in accordance with
Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price
of $13.90 per share, which is equal to the closing price of
BioCryst common stock on the grant date. The options and RSUs
vest in four equal annual installments beginning on the one-year
anniversary of the grant date, in each case subject to the new
employee’s continued service with the company. Each stock option
has a 10-year term. The options and RSUs are subject to the terms
and conditions of BioCryst’s Inducement Equity Incentive Plan and a
stock option agreement or restricted stock unit agreement, as
applicable, covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. Oral, once-daily ORLADEYO®
(berotralstat) is approved in the United States and multiple global
markets. BioCryst has several ongoing development programs
including BCX9930, an oral Factor D inhibitor for the treatment of
complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva, and
galidesivir, a potential treatment for Marburg virus disease and
yellow fever. RAPIVAB® (peramivir injection) is approved in the
U.S. and multiple global markets, with post-marketing commitments
ongoing. For more information, please visit the company’s website
at www.biocryst.com.
BCRXW
Investor Contact:John Bluth+1
919 859 7910jbluth@biocryst.com
Media Contact:Catherine
Collier Kyroulis+1 917 886 5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024